Teleflex orporated found using ticker (TFX) have now 9 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 455 and 325 and has a mean target at 408.56. Now with the previous closing price of 347.05 this now indicates there is a potential upside of 17.7%. The 50 day moving average now sits at 326.45 and the 200 moving average now moves to 358.05. The company has a market capitalisation of $16,392m. You can visit the company’s website by visiting: https://www.teleflex.com
The potential market cap would be $19,298m based on the market concensus.
Teleflex orporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, luding metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology product comprises the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, luding oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was orporated in 1943 and is headquartered in Wayne, Pennsylvania.
